GlassScriptPhysician profile
Jeffrey W Hawk
NPI 1215223433
$248.82
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $28.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $58.82 | 2019 | |
| Aquestive Therapeutics, INC. | $46.56 | 2019-2020 | |
| Ucb, INC. | $44.66 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $34.64 | 2019 | |
| Genzyme Corporation | $20.28 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.36 | 2019 | |
| Greenwich Biosciences, INC. | $13.26 | 2019 | |
| Acorda Therapeutics, INC | $11.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hawk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.